Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of Sleep CALM nocturia factors in a male veteran population.
Monaghan TF, Fang A, Ksido LR, Hachicho C, Muneeb M, Rahman SN, Bou Kheir G, Lazar JM, Everaert K, Wein AJ, Weiss JP. Monaghan TF, et al. Among authors: wein aj. Neurourol Urodyn. 2024 Mar 21. doi: 10.1002/nau.25410. Online ahead of print. Neurourol Urodyn. 2024. PMID: 38511613 Review.
Editorial.
Wein AJ, Cameron AP. Wein AJ, et al. Neurourol Urodyn. 2024 Feb 20. doi: 10.1002/nau.25425. Online ahead of print. Neurourol Urodyn. 2024. PMID: 38374766 No abstract available.
Editorial.
Ginsberg DA, Clemens JQ, Cameron AP, Vasavada SP, Wein AJ. Ginsberg DA, et al. Among authors: wein aj. Neurourol Urodyn. 2024 Feb;43 Suppl 1:S5. doi: 10.1002/nau.25403. Epub 2024 Jan 30. Neurourol Urodyn. 2024. PMID: 38291826 No abstract available.
What is the best first choice oral drug therapy for OAB?
Sahai A, Robinson D, Abrams P, Wein A, Malde S. Sahai A, et al. Among authors: wein a. Neurourol Urodyn. 2024 Jan 25. doi: 10.1002/nau.25397. Online ahead of print. Neurourol Urodyn. 2024. PMID: 38270332 Review.
How do we make progress in phenotyping patients with lower urinary tract such as overactive bladder and underactive detrusor, including using urine markers and microbiome data, to personalize therapy? ICI-RS 2023-Part 2.
Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, Mancini V, de Rijk M, Tarcan T, Wein A, Abrams P, Bou Kheir G. Finazzi Agrò E, et al. Among authors: wein a. Neurourol Urodyn. 2024 Jan 4. doi: 10.1002/nau.25379. Online ahead of print. Neurourol Urodyn. 2024. PMID: 38178629
How do we make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using urine markers and microbiome data, in order to personalize therapy? ICI-RS 2023: Part 1.
Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, Mancini V, de Rijk M, Tarcan T, Wein A, Abrams P, Bou Kheir G. Finazzi Agrò E, et al. Among authors: wein a. Neurourol Urodyn. 2024 Jan 4. doi: 10.1002/nau.25377. Online ahead of print. Neurourol Urodyn. 2024. PMID: 38178627
1,446 results